SIRT Is More Cost-Effective Than Sorafenib in Locally Advanced HCC
Investigators compared the cost-effectiveness of selective internal radiotherapy (SIRT) of that of sorafenib in the locally advanced hepatocellular carcinoma setting.
Hepatocellular Carcinoma
Study Data Suggest Role for Lenvatinib in Unresectable HCC With Child-Pugh B Liver Function
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Tivozanib and Durvalumab Doublet Regimen Is Well-Tolerated in HCC
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma
[Journal of Hepatocellular Carcinoma] Researchers at UT MD Anderson Cancer Center assessed the value of chest, abdominal, and pelvic CT in the surveillance of patients with HCC, and the potential drawbacks to the practice.
Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.
FDA Denies Accelerated Approval of Keytruda Plus Lenvima for Unresectable HCC
In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.
Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.
Survival Benefit Seen With Atezolizumab-Bevacizumab Combo in Unresectable HCC
The combination resulted in durable response in many patients.
Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging
[Journal of Hepatocellular Carcinoma] In this review, the authors discuss the use of imaging techniques and radiological biomarkers to monitor treatment response in patients with advanced HCC undergoing antiangiogenic therapy, a key to decisions on whether to continue treatment or initiate second-line therapy.
Evidence Supports Efficacy, Safety of Sorafenib in Older Hispanic Patients With Advanced HCC
Retrospective analysis of older Hispanic patients with HCC treated with sorafenib have better survival than their younger counterparts, but more data are needed.
-
Loading...
-
Loading...
Next post in Liver Cancer
